Acta Scientific Clinical Case Reports (ASCR)

Editorial Volume 1 Issue 2

Challenges with Pharmacotherapy of Epilepsy in India

Arun Swaminathan*

Assistant Professor of Neurology, University of Nebraska Medical Center, Nebraska, USA

*Corresponding Author: Arun Swaminathan, Assistant Professor of Neurology, University of Nebraska Medical Center, Nebraska, USA.

Received: February 21, 2020; Published: February 24, 2020

×

  Epilepsy is estimated to afflict around 12 million people in India. Medications are the first line of therapy for this condition. Surgery would be a great choice of therapy for such patients but given the limited availability of resources and surgical centers, medical therapy remains the mainstay for most of these patients.

  Cost remains the major limiting factor for medication use. Studies worldwide show that most of the developing countries have patients that are able to spend less than 1$ / 50-70 Rs. Per day for their seizure medications. Rural parts of India certainly face this problem more acutely, although urban India is not spared from financial restrictions either. Newer medications offer greater difficulties with cost, although easy availability of generic options does offset some of these difficulties. Additional problems are faced due to the presence of sub-standard quality generic medications and spurious or fake products, which make it difficult to know if failure of therapy is true or not. Costs are especially limiting when the patient is forced to use multiple medications or higher doses of therapy for seizure control. Many patients show limited or poor compliance with the use of fewer doses often limiting their seizure control and quality of life. Increasing availability and maintenance of costs do make things relatively easier for patients but more needs to be done in this regard to improve availability and affordability of pharmacotherapy for epilepsy.

×

References

×

Citation

Citation: Arun Swaminathan. “Challenges with Pharmacotherapy of Epilepsy in India”. Acta Scientific Clinical Case Reports 1.2 (2020): 01-02.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 25, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US